PARPi Combos in Prostate Cancer
Novel PARP Inhibitor–Based Combinations Targeting Improved Patient Outcomes in Prostate Cancer

Released: April 12, 2021

Expiration: April 11, 2022

Charles Ryan
Charles Ryan, MD

Activity

Progress
1
Course Completed
PARP Inhibitor Combinations in Prostate Cancer

In this module, Charles J. Ryan, MD, offers an overview of poly(ADP-ribose) polymerase (PARP) inhibitor therapy in prostate cancer, both as a monotherapy and in novel combination regimens with androgen receptor (AR)–targeted therapies, immunotherapies, and other approaches that may further expand the number of patients with prostate cancer who benefit from PARP inhibitor (PARPi) therapy.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with prostate cancer do you provide care for in a typical month?

Which of the following describes the impact of homologous recombination repair (HRR) mutations on tumor response to single-agent PARPi?

Which of the following best describes the characteristics of patients eligible for enrollment on the phase III TALAPRO-2 clinical trial evaluating talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)?

PARP inhibition as part of combination therapies is being investigated in patients with prostate cancer for all of the following potential reasons EXCEPT which one?

In the phase I KEYNOTE-365 trial, olaparib plus pembrolizumab showed anticancer activity in which of the following patient groups with mCRPC previously treated with docetaxel?